"2-4" . "5"^^ . "V\u00FDznamn\u00FD pokrok v l\u00E9\u010Db\u011B ovari\u00E1ln\u00EDho karcinomu po 20 letech"@cs . . "CZ - \u010Cesk\u00E1 republika" . "V\u00FDznamn\u00FD pokrok v l\u00E9\u010Db\u011B ovari\u00E1ln\u00EDho karcinomu po 20 letech" . . . "The paper presents a clear survey of trends in incidence and mortality for ovarian cancer, following from recent statistical data. It summarizes the present diagnostic possibilities, the used prognostic factors and treatment schemes. A special attention is given to treatment. The treatment of persistent or relapsing illness, where significant progress has been achieved during the past 20 years by introducing bevacizumab, a new drug used in combination with carboplatin and paclitaxel. This treatment scheme is indicated as initial treatment of an advanced (III B, III C and IV stages according to FIGO) ovarian epithelial cancer, Fallopian tube cancer or primary peritoneal cancer. This scheme is becoming a new standard of care of patients with an advanced ovarian cancer."@en . "[19953F4CEABB]" . . "I" . . "1"^^ . . . "1"^^ . "F\u00EDnek, Jind\u0159ich" . "V\u00FDznamn\u00FD pokrok v l\u00E9\u010Db\u011B ovari\u00E1ln\u00EDho karcinomu po 20 letech"@cs . "1211-6645" . "An important progress in the treatment of ovarian cancer after 20 years"@en . "\u010Cl\u00E1nek p\u0159in\u00E1\u0161\u00ED p\u0159ehledn\u00E9 shrnut\u00ED trend\u016F v incidenci a mortalit\u011B na ovari\u00E1ln\u00ED karcinom vych\u00E1zej\u00EDc\u00ED z recentn\u00EDch statistick\u00FDch dat. Stru\u010Dn\u011B shrnuje sou\u010Dasn\u00E9 diagnostick\u00E9 mo\u017Enosti, u\u017E\u00EDvan\u00E9 prognostick\u00E9 faktory a l\u00E9\u010Debn\u00E1 sch\u00E9mata. Zvl\u00E1\u0161tn\u00ED pozornost v\u011Bnuje l\u00E9\u010Db\u011B. L\u00E9\u010Dba perzistuj\u00EDc\u00EDho nebo recidivuj\u00EDc\u00EDho onemocn\u011Bn\u00ED, p\u0159i n\u011Bm\u017E byly zaznamen\u00E1ny v posledn\u00EDch 20 letech v\u00FDznamn\u00E9 \u00FAsp\u011Bchy zaveden\u00EDm nov\u00E9ho l\u00E9\u010Diva bevacizumab, u\u017E\u00EDvan\u00E9ho v kombinaci s karboplatinou a paklitaxelem. Toto l\u00E9\u010Debn\u00E9 sch\u00E9ma se indikuje k \u00FAvodn\u00ED l\u00E9\u010Db\u011B pokro\u010Dil\u00E9ho (stadia III B, III C a IV dle FIGO) epitelov\u00E9ho n\u00E1doru vaje\u010Dn\u00EDk\u016F, vejcovod\u016F nebo prim\u00E1rn\u00EDho n\u00E1doru pob\u0159i\u0161nice. Toto sch\u00E9ma se st\u00E1v\u00E1 nov\u00FDm standardem p\u00E9\u010De o nemocn\u00E9 s pokro\u010Dil\u00FDm ovari\u00E1ln\u00EDm karcinomem."@cs . "V\u00FDznamn\u00FD pokrok v l\u00E9\u010Db\u011B ovari\u00E1ln\u00EDho karcinomu po 20 letech" . . "ICON 7; GOG-0218 Study; paclitaxel; ovarian cancer; carboplatin; bevacizumab"@en . "\u010Cl\u00E1nek p\u0159in\u00E1\u0161\u00ED p\u0159ehledn\u00E9 shrnut\u00ED trend\u016F v incidenci a mortalit\u011B na ovari\u00E1ln\u00ED karcinom vych\u00E1zej\u00EDc\u00ED z recentn\u00EDch statistick\u00FDch dat. Stru\u010Dn\u011B shrnuje sou\u010Dasn\u00E9 diagnostick\u00E9 mo\u017Enosti, u\u017E\u00EDvan\u00E9 prognostick\u00E9 faktory a l\u00E9\u010Debn\u00E1 sch\u00E9mata. Zvl\u00E1\u0161tn\u00ED pozornost v\u011Bnuje l\u00E9\u010Db\u011B. L\u00E9\u010Dba perzistuj\u00EDc\u00EDho nebo recidivuj\u00EDc\u00EDho onemocn\u011Bn\u00ED, p\u0159i n\u011Bm\u017E byly zaznamen\u00E1ny v posledn\u00EDch 20 letech v\u00FDznamn\u00E9 \u00FAsp\u011Bchy zaveden\u00EDm nov\u00E9ho l\u00E9\u010Diva bevacizumab, u\u017E\u00EDvan\u00E9ho v kombinaci s karboplatinou a paklitaxelem. Toto l\u00E9\u010Debn\u00E9 sch\u00E9ma se indikuje k \u00FAvodn\u00ED l\u00E9\u010Db\u011B pokro\u010Dil\u00E9ho (stadia III B, III C a IV dle FIGO) epitelov\u00E9ho n\u00E1doru vaje\u010Dn\u00EDk\u016F, vejcovod\u016F nebo prim\u00E1rn\u00EDho n\u00E1doru pob\u0159i\u0161nice. Toto sch\u00E9ma se st\u00E1v\u00E1 nov\u00FDm standardem p\u00E9\u010De o nemocn\u00E9 s pokro\u010Dil\u00FDm ovari\u00E1ln\u00EDm karcinomem." . "An important progress in the treatment of ovarian cancer after 20 years"@en . . . . . . "180264" . . "11140" . "16" . "RIV/00216208:11140/12:10133384" . "RIV/00216208:11140/12:10133384!RIV13-MSM-11140___" . . . "Praktick\u00E1 gynekologie" . . .